Co-Diagnostics Inc
NASDAQ:CODX
Operating Margin
Co-Diagnostics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Co-Diagnostics Inc
NASDAQ:CODX
|
9.4m USD |
-1 097%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
215.2B USD |
18%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
185.9B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
153.3B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148.8B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
114.9B USD |
20%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.7B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.3B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.5B USD |
29%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.2B CNY |
34%
|
Co-Diagnostics Inc
Glance View
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Co-Diagnostics Inc's most recent financial statements, the company has Operating Margin of -1 097.2%.
You don't have any saved screeners yet